As of July 1, 2023, Medicare has launched the Bridge program, allowing select beneficiaries access to GLP-1 medications for weight management, marking a significant policy change in the coverage of obesity treatments.
On July 1, 2023, Medicare introduced the Bridge program, a new initiative aimed at providing access to weight management medications, specifically GLP-1 receptor agonists, for individuals aged 65 and older, as well as other eligible Medicare beneficiaries. This policy change signifies a shift in the long-standing prohibition against Medicare coverage for weight-loss medications, which has been a contentious issue for decades.
The Bridge program is a response to growing recognition of obesity as a complex disease with serious health implications. This change was initiated during the previous presidential administration, reflecting an evolving understanding of the need for effective obesity treatments. However, the new program has limitations, as it does not cover all available weight management medications or the additional services necessary for sustained weight loss.
Eligibility Criteria and Coverage Limitations
To qualify for the Bridge program, beneficiaries must have Medicare Part D prescription drug coverage, either through a Medicare Advantage plan or a standalone Part D plan. Notably, those whose prescription drug benefits are provided through employer-sponsored plans may not be eligible, and it’s essential for beneficiaries to verify their plan’s status.
Under the Bridge program, only certain GLP-1 medications are covered, and beneficiaries must meet specific health criteria. For instance, individuals with a body mass index (BMI) of 35 or higher automatically qualify. Those with a BMI of 27 or higher may qualify if they have certain medical conditions, such as prediabetes or a history of cardiovascular events. However, individuals already receiving GLP-1 medications for other conditions, such as Type 2 diabetes, are ineligible for coverage under the Bridge program.
Demand and Anticipated Impact
Dr. Lauren Oshman, a physician specializing in family and obesity medicine at the University of Michigan Health, has been closely involved in preparing for the launch of the Bridge program. She expressed optimism about the program, citing a survey conducted by the U-M National Poll on Healthy Aging, which found that nearly 76% of older adults believe Medicare should cover weight-loss medications. Furthermore, 60% of respondents aged 50 to 80 with a BMI of 30 or above showed interest in weight management medications.
“Based on our data, and on the calls to my clinic in the last few weeks, I think there is going to be robust demand under the Bridge program,” said Oshman. “I’m thrilled that GLP-1-based medications like semaglutide (Wegovy) and tirzepatide (Zepbound) are going to be covered under Medicare, but several important medications are not.”
Cost and Financial Implications
The Bridge program charges beneficiaries a monthly fee of $50 for their GLP-1 prescriptions, which does not apply to their prescription spending cap for Medicare. This fee could be a significant financial consideration for those on fixed incomes. Additionally, low-income beneficiaries may find that the monthly fee does not qualify for reductions available through programs like Extra Help.
Although this cost is set to be outside the annual cap on drug spending, beneficiaries must still navigate the complexities of their overall medication expenses. For instance, the proposed maximum spending cap for Medicare beneficiaries is projected to rise from $2,100 in 2026 to $2,400 in 2027.
Concerns About Program Limitations
While the Bridge program marks a step forward in coverage for obesity treatment, it lacks comprehensive support services that are critical for successful weight management. Research indicates that patients tend to achieve better results when they receive additional support, such as dietary counseling and ongoing health monitoring. However, the Bridge program does not mandate such services, raising concerns among experts like Dr. Oshman.
“It takes more than just a prescription to achieve sustained weight loss and the health benefits that go along with it,” Oshman noted. “It takes wraparound services and support, none of which is addressed in the Bridge program.”
Future Directions and Legislative Considerations
Looking ahead, the Medicare system is planning to develop a successor to the Bridge program named Balance, set to launch in January 2028. However, this initiative currently lacks Congressional funding, leaving uncertainty about its future and how it will affect beneficiaries’ access to weight management medications.
As the Bridge program unfolds, it is essential for beneficiaries, healthcare providers, and policymakers to monitor its impact on access to GLP-1 medications and the overall effectiveness of obesity management strategies under Medicare. The introduction of this program reflects an important development in public health policy, emphasizing the need for ongoing dialogue about the treatment of obesity as a public health priority.
No Comment! Be the first one.